News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
150 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17844)
Month
January (2883)
February (2030)
March (1769)
April (2200)
May (2664)
June (3162)
July (3087)
August (3801)
September (4260)
October (5136)
November (4629)
December (3503)
Day
1 (168)
2 (76)
4 (3)
5 (150)
6 (144)
7 (139)
8 (146)
9 (72)
10 (4)
11 (1)
12 (157)
13 (167)
14 (125)
15 (111)
16 (54)
17 (4)
19 (20)
20 (49)
21 (57)
22 (62)
23 (38)
25 (1)
26 (79)
27 (106)
28 (97)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
4
5
6
7
8
9
10
11
12
13
14
15
16
17
19
20
21
22
23
25
26
27
28
Business
ICU Medical Announces Time of Fourth Quarter and Fiscal Year 2017 Earnings Conference Call
The Company will release its fourth quarter and fiscal year 2017 results on Thursday, March 1st, 2018.
February 5, 2018
·
1 min read
Policy
Paratek Completes Submission of NDAs to the FDA for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections
The FDA has previously granted omadacycline both Qualified Infectious Disease Product and Fast Track designation for these indications.
February 5, 2018
·
3 min read
Biotech Beach
Metagenics Joins the UC San Diego Center for Microbiome Innovation as an Industry Sponsor
Metagenics has joined the UC San Diego Center for Microbiome Innovation as an industry sponsor.
February 5, 2018
·
3 min read
BioMidwest
miRagen Therapeutics Announces Proposed Public Offering of Common Stock
All of the common stock is being offered by miRagen
February 5, 2018
·
6 min read
Business
Addex Provides Key Financial Indicators and Trading Update
Addex completed 2017 with a cash postion of CHF2.6 million.
February 5, 2018
·
3 min read
University of Copenhagen Installs Latest MILabs VECTor5CT System to Further Accelerate Neuroscience Research.
MILabs announced today that it has successfully completed the installation of its top-of-the-line multimodality PET-SPECT-UHR CT in the laboratory of Prof. Maiken Nedergaard, M.D, D.M.Sci. - Center for Translational Neuroscience, Division of Glial Disease and Therapeutics.
February 5, 2018
·
2 min read
Business
Digirad Announces Closing of Sale of its MDSS Service Contracts to Philips North America
The MDSS Service business provided post warranty contract maintenance services for large diagnostic imaging equipment.
February 5, 2018
·
2 min read
Business
Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Feb. 5, 2018
The stock options have an exercise price of $22.31 per share and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
February 5, 2018
·
1 min read
Pharm Country
InventHelp Release: Inventors Develop Injury Healing System
The system is ideal for athletes, sports enthusiasts, medical facilities, etc.
February 5, 2018
·
1 min read
Business
Parkinson’s Institute and Clinical Center Collaborates with Merck to Evaluate LRRK2 Kinase Inhibition in Preclinical Model of Parkinson’s Disease
The Parkinson’s Institute and Clinical Center has entered into a collaboration with Merck, known as MSD outside the United States and Canada, to study the effects of LRRK2 kinase inhibitors on non-motor symptoms in a preclinical model of gastrointestinal (GI) dysfunction in Parkinson’s disease.
February 5, 2018
·
2 min read
Previous
10 of 15
Next